What is the effect of ribociclib combined with endocrine therapy in the treatment of breast cancer?

Ribociclib is a targeted drug that is a CDK4/6 inhibitor and is often used in combination with endocrine therapy to treat HR-positive, HER2-negative metastatic or locally advanced breast cancer. CDK4/6 inhibitors inhibit the proliferation of tumor cells by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), especially the proliferation of HR-positive breast cancer cells.

The combination of endocrine therapy (such as tamoxifen or aromatase inhibitors) and ribociclib has achieved clinically significant efficacy. Studies have shown that the combination of ribociclib and endocrine therapy can significantly improve progression-free survival (PFS), which is more significant than the use of endocrine therapy alone. Ribociclib blocks the proliferation of tumor cells, slows down tumor growth and prolongs patients' disease-free survival.

According to clinical trials, such as the MONALEESA-2 and MONALEESA-7 studies, ribociclib combined with endocrine therapy significantly improved the therapeutic effect in patients with HR-positive, HER2-negative breast cancer. These studies show that ribociclib combined with tamoxifen or aromatase inhibitors can significantly prolong the progression-free survival of patients, and compared with traditional single endocrine therapy, the efficacy of the combination treatment group is superior. Especially for patients with advanced breast cancer, combined treatment can significantly improve the quality of life and slow down the progression of the disease.
In addition, the safety of ribociclib has also received widespread attention. Most patients experience tolerable side effects when using ribociclib combination therapy, such as mild hypoleukemia, abnormal liver function, etc., and these side effects can usually be managed by adjusting the dose. Despite certain side effects, the combined use of ribociclib and endocrine therapy undoubtedly provides a new treatment option for patients with HR-positive breast cancer, especially those for whom traditional endocrine therapy is ineffective or whose disease progresses rapidly.
Ribociclib, used in combination with endocrine therapy, provides significant therapeutic benefits for patients with HR-positive, HER2-negative breast cancer, especially those with advanced or metastatic breast cancer. Combination therapy can significantly extend progression-free survival and improve patient prognosis. Although there may be some side effects, its efficacy and tolerability make it an important option for the treatment of breast cancer.
Reference: https://us.kisqali.com/